Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary progressive multiple sclerosis (SPMS). SPMS is a progressive and highly disabling form of MS, and remains an area of significant unmet medical need - Novartis continues to build on its experience and expertise in MS to advance care for people with the condition Basel, September 17, 2016 - Novartis today announced positive results of the Phase III EXPAND study showing that oral once-daily BAF312 (siponimod) significantly reduced the risk of disability progression compared with placebo in people with secondary progressive multiple sclerosis (SPMS). SPMS is a form of MS characterized by continuous worsening of neurological function over time, independent of relapses. Topline results of EXPAND were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), in London, UK. BAF312 is a scientifically designed, selective sphingosine-1-phosphate (S1P) receptor modulator. Initial data from the EXPAND study show: Treatment with BAF312 reduced the risk of three-month confirmed disability progression by 21% compared with placebo (p=0. The risk reduction for six-month confirmed disability progression was greater, further supporting robustness of the data.
